Endo International PLC (ENDP) Releases FY17 Earnings Guidance
Endo International PLC (NASDAQ:ENDP) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.35-3.65 for the period, compared to the Thomson Reuters consensus estimate of $3.53. The company issued revenue guidance of $3.38-3.53 billion, compared to the consensus revenue estimate of $3.49 billion.
Several research firms have recently weighed in on ENDP. Oppenheimer Holdings, Inc. reaffirmed a hold rating on shares of Endo International PLC in a research note on Tuesday. Royal Bank Of Canada lifted their price objective on Endo International PLC from $9.00 to $15.00 and gave the company a sector perform rating in a research note on Wednesday. Guggenheim began coverage on Endo International PLC in a research note on Saturday, June 17th. They issued a hold rating and a $12.00 price objective on the stock. BidaskClub lowered Endo International PLC from a hold rating to a sell rating in a research note on Monday, July 31st. Finally, Canaccord Genuity set a $12.00 price target on Endo International PLC and gave the stock a hold rating in a research report on Thursday, June 8th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of Hold and an average price target of $17.18.
Shares of Endo International PLC (NASDAQ:ENDP) traded up 2.93% during midday trading on Wednesday, hitting $8.42. The stock had a trading volume of 4,454,170 shares. The firm has a 50-day moving average of $11.36 and a 200 day moving average of $11.72. Endo International PLC has a 12-month low of $7.90 and a 12-month high of $24.93. The firm’s market cap is $1.88 billion.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. During the same quarter last year, the company earned $0.86 EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis. On average, analysts expect that Endo International PLC will post $3.53 earnings per share for the current year.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.